Becton Dickinson and Company (NYSE:BDX) shares fell to a low of $238.79 before closing at $240.54. Intraday shares traded counted 2.54 million, which was -82.76% lower than its 30-day average trading volume of 1.39M. BDX’s previous close was $240.25 while the outstanding shares total 291.10M. The firm has a beta of 0.77, a 12-month trailing P/E ratio of 42.81, and a growth ratio of 3.67. The stock’s Relative Strength Index (RSI) is 44.73, with weekly volatility at 1.27% and ATR at 3.51. The BDX stock’s 52-week price range has touched low of $219.50 and a $284.97 high. The stock traded higher over the last trading session, gaining 0.12% on 06/18/21.
Investors have identified the Medical Instruments & Supplies company Becton Dickinson and Company as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $69.87 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Becton Dickinson and Company (BDX) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 10.0 billion total, with 5.38 billion as their total liabilities.
BDX were able to record 2.22 billion as free cash flow during the 08/12/2021 quarter of the year, this saw their quarterly net cash flow reduce by 981.0 million. In cash movements, the company had a total of 2.72 billion as operating cash flow.
Potential earnings growth for Becton Dickinson and Company (BDX)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 08/12/2021 quarter of the year, Becton Dickinson and Company recorded a total of 4.91 billion in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 13.33% coming in sequential stages and their sales for the 08/12/2021 quarter reducing by -8.31%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 2.66 billion trying to sell their products during the last quarter, with the result yielding a gross income of 2.25 billion. This allows shareholders to hold on to 291.10M with the recently reported earning now reading 1.03 cents per share. This is a figure that compared to analyst’s prediction for their 08/12/2021 (3.19 cents a share).
Having a look at the company’s valuation, the company is expected to record 13.08 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on BDX sounds very interesting.
Is the stock of BDX attractive?
In related news, Executive Vice President, Lim James C sold 3,429 shares of the company’s stock in a transaction that recorded on May 28. The sale was performed at an average price of 241.68, for a total value of 828,721. As the sale deal closes, the Director, Fraser Claire now sold 390 shares of the company’s stock, valued at 94,130. Also, EVP and President, EMEA, Goette Roland sold 930 shares of the company’s stock in a deal that was recorded on Nov 23. The shares were price at an average price of 230.10 per share, with a total market value of 213,993. Following this completion of acquisition, the EVP & Pres Life Sciences, Kaltenbach Patrick now holds 1,272 shares of the company’s stock, valued at 330,720. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.20%.
10 out of 19 analysts covering the stock have rated it a Buy, while 8 have maintained a Hold recommendation on Becton Dickinson and Company. 0 analysts has assigned a Sell rating on the BDX stock. The 12-month mean consensus price target for the company’s shares has been set at $278.40.